# US 12,215,106 B2 · Pharmaceutical compounds and therapeutic methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,215,106 B2
- Document ID: US12215106B2
- Status: Granted
- Kind: B2
- Application number: 17/297,397
- Filed: 2019-11-26
- Published: 2022-01-06
- Granted: 2025-02-04
- Earliest claimed: 2018-11-27
- Assignees: Rutgers, The State University of New Jersey
- Applicants: Rutgers, the State University of New Jersey
- Inventors: David J. Augeri; Hatim Sabaawy; John A. Gilleran
- Web page: https://patentgrep.com/patent/US12215106B2

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The invention provides compounds of formula (16) and (17); and salts thereof, as well as compositions comprising such compounds and salts, complexes comprising such compounds and salts, and methods for treating cancer, inhibiting BMI1 expression, or treating Huntington's disease using such compounds, salts, and complexes. The compounds, salts, and complexes have potency, permeability, and oral bioavailability that make them particularly useful, for example, for the treatment of glioblastoma.

## Claims

### Claim 1

A compound, which is:
or salt thereof.

### Claim 2 (depends on 1)

A pharmaceutical composition, comprising, the compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

A method for treating glioblastoma in an animal comprising administering to the animal an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.